Nuvelo Inc

Introduction

Nuvelo is a biopharmaceutical company that is focused on the discovery, development, and commercialization of novel drugs for acute cardiovascular and cancer therapy primarily in the US. The company's lead candidate, NU172, is a Phase I product candidate indicated for the treatment of acute cardiovascular procedures, such as coronary artery bypass graft (CABG) surgery.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase I for use as a potential short-acting anticoagulant during medical or surgical procedures and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. Nuvelo derived entire revenues from collaboration agreements associated with the company's license and collaboration agreement with Bayer for the development and commercialization of alfimeprase internationally during 2006. During 2002-2006, it's total revenues decreased considerably at a CAGR of 38% during 2002-2006 from $26 million to $4 million. Nuvelo's sole contributor to sales growth out to 2010 will be the license, collaboration and other revenues earned in connection with the development and commercialization of product candidates such as NU172 and NU206 from its collaborators, Archemix and Kirin Brewery respectively.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .